Table 1.

Comparison of mogamulizumab with other systemic treatment options for CTCL

Drugs	Study/reference	Disease	N	Phase	Median prior lines	ORR (%)	PFS (months)	DOR (months)
Mogamulizumab	Ogura et al (2014)50	PTCL, CTCL	37	2	2	38a	3.0	NR
Mogamulizumab	Duvic et al (2015)55	CTCL	42	1/2	3	37	11.4	10.4
Mogamulizumab	Kim et al (2018)36	CTCL	186	3	3	28	7.7	14.1
Alemtuzumab	Lundin et al (2003)31	CTCL	22	2	3	55	NR	12.0
Belinostat	Foss et al (2015)19	PTCL, CTCL	53	2	4	14a	1.4a,b	2.7a
Bendamustine	Damaj et al (2013)20	PTCL, CTCL	60	2	1	50	3.6	3.5
Bexarotene	Duvic et al (2001)21	CTCL	94	2	5	45, 55c	NR	9.8, 12.6c
Bexarotene (59%) or methotrexate (41%)b	Prince et al (2017)23	CD30+ CTCL	64	3	4	13	3.5	18.3
Brentuximab vedotin	Prince et al (2017)23	CD30+ CTCL	66	3	4	56	16.7	15.1
Denileukin diftitox	Prince et al (2010)22	CD25+ CTCL	144	3	2	44	26.0	7.8
Lenalidomide	Querfeld et al (2014)27	CTCL	32	2	6	28	8.0	10.0
Pembrolizumab	Khodadoust et al (2016)26	CTCL	24	2	4	38	NR	NR
Pralatrexate	Horwitz et al (2012)25	CTCL	54	1/2	4	41	12.7	Not reached
Pralatrexate and bexarotene	Duvic et al (2017)24	CTCL	34	1/2	3.5	60	12.8	>29
Romidepsin	Whittaker et al (2010)29	CTCL	96	2	4	34	8.0d	15.0
Vorinostat	Olsen et al (2007)28	CTCL	74	2c	3	30	1.8d	>6.1
Vorinostat	Kim et al (2018)36	CTCL	186	3	3	5	3.1	9.1

Note:

^aCTCL patients only,

^bcontrol arm (physician’s choice) of the ALCANZA trial,

^cbexarotene dose 300 mg/m²/d and >300 mg/m²/d, respectively,

^dtime to progression reported rather than PFS.

Abbreviations: CTCL, cutaneous T-cell lymphoma; DOR, duration of remission; NR, not reported; ORR, overall response rate; PFS, progression-free survival; PTCL, peripheral T-cell lymphoma.